E11.21

Type 2 diabetes mellitus with diabetic nephropathy

Type 2 diabetes mellitus with diabetic nephropathy represents a microvascular complication of diabetes characterized by progressive kidney damage. Pathophysiologically, chronic hyperglycemia leads to the formation of advanced glycation end products (AGEs) and the activation of various metabolic pathways that cause oxidative stress and inflammation within the renal glomeruli. This results in the thickening of the glomerular basement membrane, mesangial expansion, and the development of Kimmelstiel-Wilson nodules (nodular glomerulosclerosis). Hemodynamic changes, such as glomerular hyperfiltration and increased intraglomerular pressure, further contribute to glomerular scarring and the eventual loss of nephron function. Left untreated, it is a leading cause of end-stage renal disease (ESRD), requiring dialysis or transplantation. Management focuses on rigorous glycemic control, blood pressure regulation (typically with ACE inhibitors or ARBs), and emerging therapies like SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists.

Clinical Symptoms

Microalbuminuria (early stage, often asymptomatic)
Macroalbuminuria (persistent protein in urine)
Foamy urine appearance (due to excess protein)
Peripheral edema (swelling in ankles, feet, or hands)
Periorbital edema (puffiness around the eyes)
Worsening hypertension or difficult-to-control blood pressure
Increased frequency of urination (polyuria), particularly at night (nocturia)
Generalized fatigue and lethargy
Loss of appetite or metallic taste in the mouth
Nausea and vomiting in advanced stages (uremic symptoms)
Difficulty concentrating or confusion
Muscle twitching or cramping

Common Causes

Chronic hyperglycemia (primary driver of microvascular damage)
Long-standing, poorly controlled Type 2 diabetes mellitus
Arterial hypertension (exacerbates glomerular pressure and damage)
Genetic predisposition and family history of diabetic kidney disease
Hyperlipidemia (contributes to renal lipid toxicity)
Tobacco use (accelerates renal function decline)
Obesity and metabolic syndrome
Advanced Glycation End Products (AGEs) accumulation
Systemic inflammation and oxidative stress

Documentation & Coding Tips

Explicitly link kidney disease to diabetes using causal language.

Example: Patient with type 2 diabetes mellitus complicated by diabetic nephropathy and stage 3a chronic kidney disease. Current eGFR is 52 mL/min/1.73m2. The nephropathy is a direct manifestation of long-standing hyperglycemia. Billing focus: Explicit causal relationship. Risk adjustment: Assigns HCC 18 (Diabetes with Complications) and HCC 138 (CKD Stage 3).

Billing Focus: Causal link documentation (e.g., due to, with, or manifestation of) to support E11.21 and N18 series.

Always document the specific stage of Chronic Kidney Disease separately.

Example: 65-year-old male with type 2 diabetes mellitus and associated nephropathy. Laboratory findings show persistent albuminuria (UACR 350 mg/g) and eGFR of 28, consistent with CKD stage 4. Billing focus: Secondary code N18.4 for CKD stage. Risk adjustment: CKD Stage 4 significantly increases the risk score compared to unspecified stages.

Billing Focus: Requirement of a secondary code from the N18 series to specify the severity of renal involvement.

Specify use of insulin or injectable non-insulin antidiabetics for long-term management.

Example: Diabetes type 2 with nephropathy, currently managed with long-term basal insulin glargine and semaglutide injections. CKD stage 3b present. Billing focus: Z79.4 for insulin or Z79.85 for non-insulin injectables. Risk adjustment: Long-term insulin use is a status code that supports treatment complexity.

Billing Focus: Code Z79.4 (Long term use of insulin) or Z79.85 (Long-term use of injectable non-insulin antidiabetic drugs) must be added.

Include specific manifestations such as Kimmelstiel-Wilson disease if applicable.

Example: Biopsy-confirmed Kimmelstiel-Wilson lesion in a patient with type 2 diabetes and nephrotic range proteinuria. Billing focus: E11.21 includes intercapillary glomerulosclerosis. Risk adjustment: Validates the specificity of the diabetic complication through pathological evidence.

Billing Focus: Specific pathological terms like Kimmelstiel-Wilson or intercapillary glomerulosclerosis map directly to E11.21.

Document associated hypertensive kidney disease as a separate co-morbidity.

Example: Patient presents with type 2 diabetes with nephropathy and hypertensive chronic kidney disease, stage 3. Blood pressure 155/92. Billing focus: Requires E11.21, I12.9, and N18.30. Risk adjustment: Multiple chronic condition codes (Diabetes, Hypertension, CKD) increase total risk score.

Billing Focus: Co-coding for hypertensive CKD (I12.-) alongside diabetic nephropathy (E11.21).

Relevant CPT Codes

99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a Low level of medical decision making or 20-29 minutes of total time
Applies to straightforward management of chronic stable conditions.
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a Moderate level of medical decision making or 30-39 minutes of total time
Common for patients with multiple diabetic complications or advancing CKD stages.
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a High level of medical decision making or 40-54 minutes of total time
Reflects the high complexity of managing end-stage diabetic complications.
82043 - Albumin; urine (eg, microalbumin), quantitative
Essential diagnostic tool for identifying and monitoring diabetic nephropathy.
82565 - Creatinine; blood
Standard of care for assessing renal function in diabetic patients.
82570 - Creatinine; other source
Used to calculate the albumin-to-creatinine ratio (UACR).
76770 - Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete
Used when kidney function declines to differentiate diabetic damage from obstruction.
95250 - Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours
Managing glycemia strictly is the primary treatment for slowing nephropathy.
93000 - Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
Diabetic nephropathy carries a very high cardiovascular risk profile.
99401 - Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes
Supports the intensive education required for kidney preservation.